JPWO2019226685A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019226685A5 JPWO2019226685A5 JP2020565354A JP2020565354A JPWO2019226685A5 JP WO2019226685 A5 JPWO2019226685 A5 JP WO2019226685A5 JP 2020565354 A JP2020565354 A JP 2020565354A JP 2020565354 A JP2020565354 A JP 2020565354A JP WO2019226685 A5 JPWO2019226685 A5 JP WO2019226685A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- mtor inhibitor
- nanoparticle
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 50
- 229940124302 mTOR inhibitor Drugs 0.000 claims 16
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 16
- 239000002105 nanoparticle Substances 0.000 claims 16
- 208000002815 pulmonary hypertension Diseases 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 7
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 6
- 102000014914 Carrier Proteins Human genes 0.000 claims 5
- 108010078791 Carrier Proteins Proteins 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 2
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 claims 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 2
- 208000020193 Pulmonary artery hypoplasia Diseases 0.000 claims 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 108010090549 Endothelin A Receptor Proteins 0.000 claims 1
- 102100040630 Endothelin-1 receptor Human genes 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 208000021066 Pulmonary arterial hypertension associated with connective tissue disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical class O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675110P | 2018-05-22 | 2018-05-22 | |
| US62/675,110 | 2018-05-22 | ||
| US201962810290P | 2019-02-25 | 2019-02-25 | |
| US62/810,290 | 2019-02-25 | ||
| US201962820838P | 2019-03-19 | 2019-03-19 | |
| US201962820842P | 2019-03-19 | 2019-03-19 | |
| US62/820,838 | 2019-03-19 | ||
| US62/820,842 | 2019-03-19 | ||
| PCT/US2019/033372 WO2019226685A1 (en) | 2018-05-22 | 2019-05-21 | Methods and compositions for treating pulmonary hypertension |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021526138A JP2021526138A (ja) | 2021-09-30 |
| JPWO2019226685A5 true JPWO2019226685A5 (https=) | 2022-05-27 |
| JP2021526138A5 JP2021526138A5 (https=) | 2022-05-27 |
| JP7561628B2 JP7561628B2 (ja) | 2024-10-04 |
Family
ID=68615837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565354A Active JP7561628B2 (ja) | 2018-05-22 | 2019-05-21 | 肺高血圧症を処置するための方法および組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210085621A1 (https=) |
| EP (1) | EP3810091A4 (https=) |
| JP (1) | JP7561628B2 (https=) |
| KR (1) | KR20210024471A (https=) |
| CN (1) | CN112423737A (https=) |
| AU (1) | AU2019274516B2 (https=) |
| BR (1) | BR112020023431A2 (https=) |
| CA (1) | CA3100905A1 (https=) |
| IL (1) | IL278814A (https=) |
| MX (2) | MX2020012478A (https=) |
| NZ (1) | NZ770290A (https=) |
| SG (1) | SG11202011462SA (https=) |
| TW (1) | TW202015659A (https=) |
| WO (1) | WO2019226685A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| PL3998069T3 (pl) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| MX2021011230A (es) * | 2019-03-19 | 2022-03-11 | Abraxis Bioscience Llc | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. |
| JP7832108B2 (ja) | 2019-10-28 | 2026-03-17 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| KR20220120823A (ko) | 2021-02-24 | 2022-08-31 | 주식회사 만도 | 랙구동형 동력 보조 조향장치 |
| CN114732789B (zh) * | 2022-05-05 | 2023-08-22 | 中国药科大学 | 一种用于治疗肺动脉高压的复方长效递药系统及其制备 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| CN105879114A (zh) | 2005-02-18 | 2016-08-24 | 阿布拉西斯生物科学公司 | 用于整合入医疗装置的疏水性改善的药物 |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2008109163A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| KR20170095807A (ko) * | 2014-10-07 | 2017-08-23 | 램 테라퓨틱스, 인코포레이티드 | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 |
| US20180256551A1 (en) * | 2015-06-29 | 2018-09-13 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| HK1247093A1 (zh) * | 2015-06-29 | 2018-09-21 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法 |
| US20180177771A1 (en) * | 2015-06-29 | 2018-06-28 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
| PL3998069T3 (pl) * | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| EP3518923A4 (en) * | 2016-09-28 | 2020-06-17 | Abraxis BioScience, LLC | METHOD FOR TREATING MITOCHONDRIAL AND METABOLIC DISORDERS |
-
2019
- 2019-05-21 CN CN201980048031.5A patent/CN112423737A/zh active Pending
- 2019-05-21 TW TW108117571A patent/TW202015659A/zh unknown
- 2019-05-21 EP EP19807397.5A patent/EP3810091A4/en active Pending
- 2019-05-21 KR KR1020207036401A patent/KR20210024471A/ko not_active Ceased
- 2019-05-21 AU AU2019274516A patent/AU2019274516B2/en not_active Expired - Fee Related
- 2019-05-21 CA CA3100905A patent/CA3100905A1/en active Pending
- 2019-05-21 NZ NZ770290A patent/NZ770290A/en unknown
- 2019-05-21 WO PCT/US2019/033372 patent/WO2019226685A1/en not_active Ceased
- 2019-05-21 BR BR112020023431-1A patent/BR112020023431A2/pt unknown
- 2019-05-21 JP JP2020565354A patent/JP7561628B2/ja active Active
- 2019-05-21 MX MX2020012478A patent/MX2020012478A/es unknown
- 2019-05-21 SG SG11202011462SA patent/SG11202011462SA/en unknown
-
2020
- 2020-11-18 IL IL278814A patent/IL278814A/en unknown
- 2020-11-19 US US16/953,167 patent/US20210085621A1/en active Pending
- 2020-11-20 MX MX2024010373A patent/MX2024010373A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526138A5 (https=) | ||
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| CN100558364C (zh) | 用于局部眼科应用的溴莫尼定和噻吗洛尔的组合 | |
| CN101511364B (zh) | 用于糖尿病的治疗组合 | |
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| US20110052580A1 (en) | Use of picoplatin and bevacizumab to treat colorectal cancer | |
| US20100267735A1 (en) | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | |
| US20140343148A1 (en) | Prophylactic or therapeutic agent for idiopathic inflammatory myopathies | |
| JP2017128610A (ja) | 併用ａｌｓ療法 | |
| JP2022502492A5 (https=) | ||
| JPWO2019226685A5 (https=) | ||
| CN1726041A (zh) | 含有非核苷反转录酶抑制剂(nnrti)以及细胞色素p450抑制剂如蛋白酶抑制剂的组合物的用途 | |
| JP2020517660A (ja) | ２−アミノ−ｌ−（２−（４−フルオロフェニル）−３−（４−フルオロフェニルアミノ）−８，８−ジメチル−５，６−ジヒドロイミダゾ［１，２−ａ］ピラジン−７（８ｈ）−イル）エタノン及びそれらの組み合わせの治療レジメン | |
| TWI776451B (zh) | Bcl-2/bcl-xl抑制劑之組合及相關用途 | |
| WO1998024411A2 (en) | Method for oral administration of buspirone | |
| US20030087911A1 (en) | Methods and compositions for treating hypertension | |
| US10258617B2 (en) | Dosing regimens for fast onset of antidepressant effect | |
| US20080113952A1 (en) | Combination Therapy For Treating Heart Disease | |
| JP2013510866A (ja) | 組み合わせたチボザニブおよびテムシロリムス | |
| RU2020142051A (ru) | Способы и композиции для лечения легочной гипертензии | |
| CN1976708A (zh) | 包含bcrp抑制剂和4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－(4－吡啶－3－基)嘧啶－2－基氨基)苯基]－苯甲酰胺的组合 | |
| EP4640218A1 (en) | Use of sultam compound in treating biliary tract cancer | |
| CN119522109A (zh) | 用于钙调磷酸酶抑制剂的间歇性给药的组合物 | |
| WO2025221754A1 (en) | Upadacitinib for use in the treatment of giant cell arteritis | |
| WO2025259699A1 (en) | Compositions and method for treating retinal degeneration |